Department of Emergency, Zhongshan Hospital, Xiamen University, Xiamen, China.
J Biomed Mater Res A. 2012 Jun;100(6):1438-47. doi: 10.1002/jbm.a.34081. Epub 2012 Feb 29.
Although therapeutic cellular angiogenesis is effective for chronic ischemia, the optimal mode of cellular administration is still under exploration. This study aimed to develop a cellular delivery system to enhance the perfusion and angiogenesis in the ischemic hind limb. Collagen scaffold (CS) was prepared, and for morphology and toxicity analysis, bone marrow-derived mesenchymal stem cells (BMSCs) were isolated, expanded, filtrated, and seeded onto CS to construct BMSCs-CS. The ischemic hind limbs of rabbit models were implanted with autologous BMSCs-CS, CS, and autologous BMSCs; the untreated ischemic or normal animals were considered as the ischemic or normal control groups. Oxygen saturation parameters were regularly measured to determine the perfusion in the extremities. Histological examinations with hematoxylin and eosin immunostaining against von Willebrand factor and smooth muscle (SM) α-actin were performed for capillary and mature vessel evaluation. CS was a multiporous structure without cytotoxicity. At several intervals, the oxygen saturation ratio (OSR) in normal control was the highest. The OSRs in BMSCs-CS and CS were higher than that in BMSCs and ischemic control (p < 0.05); the OSR in BMSCs-CS group was higher than that in CS at 6 and 8 weeks (p < 0.05). The capillaries in BMSCs-CS and CS were higher than that in CS, BMSCs, and the ischemic or normal control (p < 0.05). The mature vessels in BMSCs-CS were higher than that in CS, BMSCs, and the ischemic or normal control (p < 0.05). The autologous cellular delivery system proved to be an effective approach for improving higher ischemic hind limb perfusion and angiogenesis as opposed to cellular therapy alone.
尽管治疗性细胞血管生成对慢性缺血有效,但细胞给药的最佳方式仍在探索中。本研究旨在开发一种细胞递送系统,以增强缺血后肢的灌注和血管生成。制备胶原支架(CS),为了形态学和毒性分析,分离、扩增、过滤和接种骨髓间充质干细胞(BMSCs)到 CS 上构建 BMSCs-CS。将兔模型的缺血后肢植入自体 BMSCs-CS、CS 和自体 BMSCs;未治疗的缺血或正常动物被认为是缺血或正常对照组。定期测量氧饱和度参数以确定四肢的灌注情况。进行苏木精和伊红免疫染色,针对血管性血友病因子和平滑肌(SM)α-肌动蛋白,进行毛细血管和成熟血管评估。CS 是一种多孔隙结构,无细胞毒性。在几个时间点,正常对照组的氧饱和度比(OSR)最高。BMSCs-CS 和 CS 的 OSR 高于 BMSCs 和缺血对照组(p < 0.05);BMSCs-CS 组在 6 周和 8 周时的 OSR 高于 CS 组(p < 0.05)。BMSCs-CS 和 CS 中的毛细血管高于 CS、BMSCs 和缺血或正常对照组(p < 0.05)。BMSCs-CS 中的成熟血管高于 CS、BMSCs 和缺血或正常对照组(p < 0.05)。与单纯细胞治疗相比,自体细胞递送系统被证明是一种有效改善更高缺血后肢灌注和血管生成的方法。